Golembiewski Michael's most recent trade in Seelos Therapeutics Inc was a trade of 417 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on Feb. 29, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Seelos Therapeutics Inc | Michael Golembiewski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.10 per share. | 29 Feb 2024 | 417 | 86,869 (0%) | 0% | 1.1 | 457 | Common Stock |
| Seelos Therapeutics Inc | Golembiewski Michael | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 24,537 | 24,537 | - | - | Stock Option (right to buy) | |
| Seelos Therapeutics Inc | Michael Golembiewski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.67 per share. | 28 Feb 2023 | 12,500 | 90,987 (0%) | 0% | 0.7 | 8,400 | Common Stock |
| Seelos Therapeutics Inc | Michael Golembiewski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (right to buy) |